| BIBLIOGRAFÍA
Bithell TC, Thrombosis and
antithrombotic therapy. En: Lee GR, Bithell TC Forester J. Athens JN, Luckns JN (eds)
Clinical Hematology Filadelfia, Lea and Febiger, 1993, 1515,1551.
- Castillo R, Ordinas A. Mecanismos de la trombogénesis
arterial y venosa. En Lopez Borrasca A, Arocha, Piñado CL, Campos Guerra CC, Parreira A,
Pavloski S, Ruiz Arguelles G, San Miguel JF (eds). Enciclopedia Iberoamericana de
hematología volumen III, Salamanca, Ediciones Universidad de Salamanca 1992: 546-562.
- Dahlback B Carlsson M, Svensson PJ, Familiar thrombofilia
due to a previously unrecognised mechanism, characterized by poor anticoagulant response
to activated protein C. Proc Natl Acad Sci USA 1993; 90 1004 -1008.
- Fuster V. Verstraete M, (eds) Thombosis in cardiovascular
disorder. Filadelfia WB, Saunders 1992.
- Hirsh J. Venous thromboembolism en: Hoffman R, Benz EJ,
Shattl SJ, Furie B, Cohen HJ (eds), Hematology Basic principles and practice Nueva York,
Churchill Livinsgtone, 1991;1465-1469.
- Paramo JA, Rocha E. Hipercoagulabilidad y
estados trombofílicos. Sangre 1991; 36; 477- 4886.
- Prentice CRM, pathogenesis of thrombosis. Hemostasis 1990,
20 (Supl 1) 50-59.
- Thomas DP. Overview of venous thrombogenesis. Semin
Thombosis Hemostas. 1988 14: 1-8.
- Dalen J.E. Alpert J.S Natural History of pulmonary
embolism. Prog. Cardiovasc. Dis. 1975 17 : 257-70
- Anderson FA, Wheeler HB. Goldberg RJ. Population based
perspective of the hospital incidence and case fatality rates of deep vein thrombosis and
pulmonary embolism. Arch Inter Med 1991; 151:933-38.
- Goldhaver SZ. Hennekens CH. Evans DA factors associated
with correct antemortem diagnosis of major pulmonary embolism in a hospital population
Br.J.Surg 1968, 55;347-52.
- Rubistein I, Murray D, Hoffstein V. Fatal pulmonary
embolism in hospitalized patients. Arch Inter Med, 1968, 148:1925-26.
- Morrell M.T. Dunhill M.S. The post mortem incidence of
pulmonary embolism in hospital population. Br. J. Surg 1968 55; 347-52
- Gaffiney, P,J, Perry M,J, Unreability of Current Serum
Fibrin Degradation Product (FDP) Assays. Throm Haemost 1985;53 (3): 301-302.
- Whitaker AN, Elms MJ, Masci PP, Bundessen PG, Rylatt DB;
Webber AJ, Bunce IH. Measurement of crosslinked derivates in plasma: an inummoassay using
monoclonal antibodies., J. Clin Pathol 1984;37:882-88716.- Kagawa K. Amano K, Kurousou K,
Ikematsu S. Thombotic disease FDP, D-Dimer, Clinical test 1989;33: 1625-1630.
- Prisco D, Panniccia R, Constanzo M, And Abbate R.
Relationship Between Enzyme Immunoassays for the detection of crosslinked fibrin
degradation Products in whole Blood. Thromb Res 1990; 58 (3):273-281.
- Rylatt DB, Kemp BE, Bundesen PG, John, O'Reilly EJ, Cottis
LE, Miles SJ, Khan JM, Dinh DP, Stapelton D, Hillyard CJ. A rapid Whole-blood immunoassays
system. Med J Aust 1990; 152: 75-77.
- Hunt Fa, Rylatt DB, Hart R-A, Bundesen PG, Serum
crosslinked fibrin (XDP) and fibrinogen degradation products (FDP) in disorders with
activation of the coagulation or fibrinolytic systems Br. J. Haematology 1985;60: 715-722.
- Fukutate K, Kuroso K, Isogain N, Shinozawa K. Clinica
Evaluation of Dimer D testing in Disseminated Intravascular Coagulation (DIC),
Fibrinolysis, 1993; 7 (suppl 2): 20-22.
- Brounameaux H, De Moerloose P, Perrier A, Reber G. Plasma
Measurement of Dimer - D as diagnostic aid suspected Venous Thromboembolism: An Overview
thomb Haemost 1004;71 (1)1-6.
|
